U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.44 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.96 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.65 (-0.90%)
     
  • Gold

    1,753.90
    -2.80 (-0.16%)
     
  • Silver

    22.36
    -0.43 (-1.90%)
     
  • EUR/USD

    1.1732
    -0.0040 (-0.34%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • GBP/USD

    1.3737
    -0.0059 (-0.43%)
     
  • USD/JPY

    109.8950
    +0.1770 (+0.16%)
     
  • BTC-USD

    48,329.14
    +1,314.02 (+2.79%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.62%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

Identiv Joins DoseID Consortium to Develop and Strengthen Industry Standards for RFID in Healthcare

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Identiv’s Innovative RFID Solutions Drive Healthcare to be Simpler, Smarter, and Safer

FREMONT, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Identiv, Inc. (NASDAQ: INVE), a global leader in digital security and identification, today announced the company joined the DoseID Consortium to strengthen its focus on radio frequency identification (RFID) applications in healthcare and participate in the development of industry standards for RFID use. DoseID connects industry participants from across the healthcare continuum to ensure RFID quality, performance, and interoperability for drug products and medical equipment. Identiv joins the consortium of leading healthcare companies sharing the mission and vision of DoseID to facilitate industry-wide collaboration for RFID healthcare standards.

Identiv RFID devices can be used in a wide range of healthcare applications, representing a significant growth opportunity for the company. Identiv offers several healthcare-focused RFID-based solutions providing secure authentication, anti-counterfeiting, transfer of patient information, temperature sensing, and monitoring and patient compliance. These solutions are currently available in the market. Identiv’s additional pipeline of healthcare applications in progress utilizes its proprietary IP, including sensor-enabled RFID devices, its patented “device on metal” solution, and a range of sustainable, eco-friendly devices.

“Identiv’s new healthcare solutions are truly innovative,” said Identiv COO Dr. Manfred Mueller, Ph.D., Chemistry. “For example, the recently launched uTrust Sense SyringeCheck is a near field communication (NFC)-enabled smart injectable dose monitoring solution ensuring patients take their medication properly. This enforces close compliance with required dosage protocols, and clinical studies can achieve compliance and trustworthy trial results.”

Dr. Mueller added: “Identiv’s membership in the DoseID Consortium reflects our vision of better patient safety and our commitment to optimizing the healthcare industry’s delivery of care with RFID. We are excited to be working with DoseID to help revolutionize and standardize RFID technology within the healthcare industry infrastructure as we continue to build our leadership position in developing Internet of Things (IoT)-connected devices.”

To learn more about Identiv’s portfolio of RFID and NFC devices for healthcare, please call +1 888.809.8880 or contact transponder_sales@identiv.com.

About Identiv
Identiv, Inc. is a global leader in digitally securing the physical world. Identiv's platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security. Identiv is a publicly traded company, and its common stock is listed on the NASDAQ Stock Market LLC in the U.S. under the symbol “INVE.” For more information, visit identiv.com.

Note Regarding Forward-Looking Information
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those involving future events and future results that are based on current expectations as well as the current beliefs and assumptions of the Company’s management and can be identified by words such as “anticipates”, “believes”, “plans”, “will”, “intends”, “expects”, and similar references to the future. Any statement that is not a historical fact, including statements regarding the Company’s expectations regarding the potential benefits of membership in the DoseID Consortium, the Company’s beliefs regarding the potential grow opportunity for its RFID devices in healthcare applications, the Company’s beliefs regarding the benefits and capabilities of its products, and the Company’s beliefs regarding the growth of its leadership position in the connected IoT market is a forward-looking statement. Forward-looking statements are only predictions and are subject to a number of risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially and adversely from those expressed in any forward-looking statements. Factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to the Company’s ability to continue the momentum in its business, its ability to successfully execute its business strategy, its ability to capitalize on trends in its business, the level and timing of customer orders, the success of its products and partnerships, industry trends and seasonality, the impact of COVID-19, the effects of shortages of semiconductors and factors discussed in its periodic reports, including its Annual Report on Form 10-K for the year ended December 31, 2020 and subsequent reports filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update such statements.

Investor Relations Contact:
Matt Glover and Sophie Pearson
Gateway Investor Relations
+1 949.574.3860
IR@identiv.com

Media Contact:
press@identiv.com